The clinical spectrum of HbSC sickle cell disease‐not a benign condition
British Journal of Haematology · 2024-08 · 205 (2) · 653-663
DOI: 10.1111/bjh.19523 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 19.06.2024. Verfasst von M Nelson und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Center for Sickle Cell Disease, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Sickle cell disease (SCD) includes a group of heterogenous disorders that result in significant morbidities. HbSS is the most common type of SCD and HbSC is the second most common type of SCD. The prevalence of HbSC disease in the United States and United Kingdom is ~1 in 7174 births and 1 in 6174 births respectively. Despite its frequency, however, HbSC disease has been insufficiently studied and was historically categorized as a more ‘mild’ form of SCD. We conducted this study of HbSC disease as part of the NHLBI funded Sickle Cell Disease Implementation Consortium (SCDIC). The SCDIC registry included 2282 individuals with SCD, ages 15–45 years of whom 502 (22%) had HbSC disease. Compared with people with sickle cell anaemia (SCA), the study found that people with HbSC disease had a higher frequency of splenomegaly ( n (%) = 169 (33.7) vs. 392 (22.1)) and retinopathy ( n (%) = 116 (23.1) vs. 189 (10.6)). A Many people with HbSC also had avascular necrosis ( n (%) = 112 (22.3)), pulmonary embolism ( n (%) = 43 (8.6)) and acute chest syndrome ( n (%) = 228 (45.4)) demonstrating significant disease severity. HbSC disease is more clinically severe than was previously recognized and deserves additional evaluation and targeted treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology/Center for Sickle Cell Disease, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
- Division of Pediatric Hematology and Oncology, Children's Mercy Hospital, Kansas City, Missouri, USA.
- Division of Biostatistics and Epidemiology, RTI International, North, Carolina, USA.
- Division of Hematology and Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.
- Division of Pediatric Hematology-Oncology, University of Illinois at Chicago, Chicago, Illinois, USA.
- Division of Hematology and Oncology, Department of Medicine, UC Davis, Sacramento, California, USA.
ORCID-Profile: V Gordeuk, T Wun, J S Hankins, A A King, J Kanter
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Nelson, M., Noisette, L., Pugh, N., Gordeuk, V., Hsu, L. L., Wun, T., Shah, N., Glassberg, J., Kutlar, A., Hankins, J. S., King, A. A., Brambilla, D., & Kanter, J. (2024). The clinical spectrum of HbSC sickle cell disease‐not a benign condition. British Journal of Haematology, 205(2), 653-663. https://doi.org/10.1111/bjh.19523
Vancouver
Nelson M, Noisette L, Pugh N, Gordeuk V, Hsu LL, Wun T, et al. The clinical spectrum of HbSC sickle cell disease‐not a benign condition. British Journal of Haematology. 2024;205(2):653-663. doi:10.1111/bjh.19523
BibTeX
@article{Nelson2024,
author = {Nelson, M and Noisette, L and Pugh, N and Gordeuk, V and Hsu, L L and Wun, T and Shah, N and Glassberg, J and Kutlar, A and Hankins, J S and King, A A and Brambilla, D and Kanter, J},
title = {The clinical spectrum of HbSC sickle cell disease‐not a benign condition},
journal = {British Journal of Haematology},
year = {2024},
volume = {205},
number = {2},
pages = {653--663},
doi = {10.1111/bjh.19523}
}
EUVIMED